Filing Details
- Accession Number:
- 0001209191-17-033405
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-05-17 18:45:18
- Reporting Period:
- 2017-05-15
- Filing Date:
- 2017-05-17
- Accepted Time:
- 2017-05-17 18:45:18
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1396814 | Pacira Pharmaceuticals Inc. | PCRX | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1296965 | Marie Kristen Williams | C/O Pacira Pharmaceuticals, Inc. 5 Sylvan Way, Suite 300 Parsippany NJ 07054 | Cao And General Counsel | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2017-05-15 | 3,125 | $9.25 | 18,775 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2017-05-15 | 5,937 | $10.52 | 24,712 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2017-05-15 | 11,979 | $10.81 | 36,691 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2017-05-15 | 21,041 | $50.86 | 15,650 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2017-05-15 | 3,125 | $0.00 | 3,125 | $9.25 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2017-05-15 | 5,937 | $0.00 | 5,937 | $10.52 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2017-05-15 | 11,979 | $0.00 | 11,979 | $10.81 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2021-10-19 | No | 4 | M | Direct | |
| 0 | 2022-03-02 | No | 4 | M | Direct | |
| 0 | 2022-06-05 | No | 4 | M | Direct |
Footnotes
- The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.75 to $51.00, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and as to the remaining option shares in successive equal monthly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.
Billionaire Hedge Funds
